Airfinity RSV Intelligence
As the RSV market continues to develop rapidly, Airfinity is committed to continued expansion of its data and intelligence coverage. In response to recent approvals, we have added data around eligible populations in each country, as well as pricing and reported revenues for the approved candidates.
Eligible Population: Understand where RSV candidates have gained approval and which populations are eligible to receive these newly approved vaccines and prophylactics. This expanded functionality allows you to:
→ Identify which markets RSV candidates have gained approval in
→ See how the eligible populations in each market differs
→ Compare the timelines of approvals in different markets
→ Understand nuances of approvals and roll-out with extra information provided e.g. shared decision making
Pricing Data: Access all publicly available pricing data across vaccines and prophylactics including public and private pricing across markets, income bands and regions. This allows you to compare pricing data across market, region, income band, country and candidate
Revenue Data: Q3 revenue data has recently been released for the first time from Sanofi for Nirsevimab, and from GSK and Pfizer for their RSV vaccines. These new reported revenue figures are now available on the platform, alongside previous reported revenues for Palivizumab. These will continue to be tracked and updated as new revenue data is released.
Get in touch to book your free demo!
Airfinity is also monitoring and collecting supply data, this will be represented on the platform in the coming weeks. Get your sneak preview by booking your demo now.
Get in touch to book your free demo!
Airfinity is also monitoring and collecting supply data, this will be represented on the platform in the coming weeks. Get your sneak preview by booking your demo now.
What our users say?
“The Airfinity report is a guide for world leaders to fix a more ambitious action plan.”
Gordon Brown, WHO Ambassador for Global Health Financing & former UK Prime Minister
“Airfinity has been instrumental in our country's COVID response.”
Head of UK Government
Vaccine Task Force
In a dynamic environment, Airfinity enabled us to remain on track with daily developments to enable more accurate decision-making. Airfinity combines nimbleness of real time data and their group of scientists that can analyse, model and provide strategic analysis for critical decision making.”
Iskra Reic, Executive Vice-President
Astrazeneca
“Probably the most expansive, accurate and helpful of the multiple data sets on an international scale”
Sir John Bell ,
University of Oxford